| Impact of superselective transarterial infusion therapy of high-dose cisplatin on maxillary cancer with orbital invasion. | |
| | |
MedLine Citation:
|
PMID: 20360344 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: We have been performing the superselective transarterial infusion of high-dose cisplatin for advanced maxillary cancer since 1998 and the local control rate, disease free survival rate, and organ preservation have improved markedly compared with our former therapy. This study evaluates the effectiveness of superselective transarterial infusion therapy by using high-dose cisplatin on maxillary cancer with orbital invasion. MATERIALS AND METHODS: We treated 23 patients with maxillary cancer by using superselective transarterial infusion therapy with high-dose cisplatin and concomitant radiation therapy for 10 years. Of all patients, 15 showed orbital invasion, with 11 of these tumors fed by both internal maxillary and ophthalmic arteries. In all patients, we performed superselective transarterial infusion therapy via the internal maxillary artery and/or the other feeding branches from the external carotid artery. After the operation, we determined whether a pCR had occurred by checking for the presence of viable cells. In addition, we calculated the overall survival rate, preservation rate of the eyeball, and disease-free survival rate. RESULTS: For all 23 patients, pCR and overall survival rates were 95.7% and 78.4%, respectively. To date, 2 of these patients died of lung metastasis without local recurrence. For the 15 patients with orbital invasion, the respective pCR and disease-free survival rates were 93.3% and 87.5%. Eyeballs were preserved in all patients, and local recurrence occurred in only 1 patient, at the inferior wall of the maxillary sinus (not in the orbit). CONCLUSIONS: Superselective transarterial infusion therapy with high-dose cisplatin remarkably improved the local control rate and disease-free survival rate of maxillary cancer. Even in patients with orbital invasion, a high local control rate was achieved, with preservation of the eyeball, through infusion only into branches of the external carotid artery. |
| | |
Authors:
|
M Kanoto; A Oda; T Hosoya; K Nemoto; A Ishida; T Nasu; S Koike; M Aoyagi |
Related Documents
:
|
21510294 - Outcomes of patients with spontaneous rupture of hepatocellular carcinoma. 21455814 - Management of high-grade retroperitoneal liposarcomas: personal experience. 21273524 - Transarterial chemoembolization can be safely performed in patients with hepatocellular... 21120644 - Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (codox-m)/ifosfam... 10416584 - Association of matrilysin expression with recurrence and poor prognosis in human esopha... 10362324 - Long-term outcome after postmastectomy radiation therapy for the treatment of ductal ca... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-04-01 |
Journal Detail:
|
Title: AJNR. American journal of neuroradiology Volume: 31 ISSN: 1936-959X ISO Abbreviation: AJNR Am J Neuroradiol Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-13 Completed Date: 2011-01-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8003708 Medline TA: AJNR Am J Neuroradiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1390-4 Citation Subset: IM |
Affiliation:
|
Department of Diagnostic Radiology, Yamagata University, Yamagata, Japan. mkanoto@med.id.yamagata-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antineoplastic Agents / administration & dosage* Carcinoma, Squamous Cell / drug therapy*, pathology, radiotherapy Carotid Artery, External Cisplatin / administration & dosage* Combined Modality Therapy Disease-Free Survival Dose-Response Relationship, Drug Female Humans Infusions, Intra-Arterial Male Maxillary Neoplasms / drug therapy*, pathology, radiotherapy Middle Aged Neoplasm Invasiveness Orbital Neoplasms / drug therapy*, pathology, radiotherapy Survival Rate |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 15663-27-1/Cisplatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Feasibility of angiographic CT in peri-interventional diagnostic imaging: a comparative study with m...
Next Document: Potent risk factor for aneurysm formation: termination aneurysms of the anterior communicating arter...